First Quarter Financial Report | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
18834
post-template-default,single,single-post,postid-18834,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

First Quarter Financial Report

First Quarter Financial Report

Moss, 9.5.2019

 

Gentian Diagnostics AS announces its results for the first quarter of 2019. The highlights include:

  • Good start to the new fiscal year with sales revenues of MNOK 10.6 for the quarter.
  • Record sales achieved for fCAL®turbo, our innovative biomarker for the diagnosis of inflammatory bowel disease.
  • New scientific study results confirm GCAL as a promising biomarker for the diagnosis of bacterial infections.

 

Please find the report and results presentation enclosed. The documents is also available on Oslo Børs.

 

Q1 2019 GD Interim presentation

Q1 2019 GD Interim report

For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

MeldingsID: 476431
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL